DRUGREBOOT.AI Trademark

Trademark Overview

On Tuesday, July 1, 2025, a trademark application was filed for DRUGREBOOT.AI with the United States Patent and Trademark Office. The USPTO has given the DRUGREBOOT.AI trademark a serial number of 99262228. The federal status of this trademark filing is ACTION CONTINUING FINAL - MAILED as of Monday, April 6, 2026. This trademark is owned by ThinkBio.ai., Inc.. The DRUGREBOOT.AI trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

International Class 42: Providing medical and scientific research information in the field of clinical trials. Drugreboot.ai is software service that analyzes a failed trial to discover molecular features associated with drug response. Drugreboot.ai combines the molecular features with the patient's clinical attributes to predict the reasons why the drug failed in the clinical trial and provides additional analysis using disease models identifies strategies for salvaging the therapy. The software provides the user with information on clinical trials failures and next steps, the main service here is that of a software services that assists those conducting clinical trials in pivoting to other uses Providing medical and scientific research information in the field of clinical trials.
drugreboot.ai

General Information

Serial Number99262228
Word MarkDRUGREBOOT.AI
Filing DateTuesday, July 1, 2025
Status649 - ACTION CONTINUING FINAL - MAILED
Status DateMonday, April 6, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Pseudo MarkDRUG REBOOT ARTIFICIAL INTELLIGENCE
Goods and ServicesInternational Class 42: Providing medical and scientific research information in the field of clinical trials. Drugreboot.ai is software service that analyzes a failed trial to discover molecular features associated with drug response. Drugreboot.ai combines the molecular features with the patient's clinical attributes to predict the reasons why the drug failed in the clinical trial and provides additional analysis using disease models identifies strategies for salvaging the therapy. The software provides the user with information on clinical trials failures and next steps, the main service here is that of a software services that assists those conducting clinical trials in pivoting to other uses Providing medical and scientific research information in the field of clinical trials.

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, July 1, 2025
Primary Code042
First Use Anywhere DateThursday, May 1, 2025
First Use In Commerce DateThursday, May 1, 2025

Trademark Owner History

Party NameThinkBio.ai., Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressOntario, CA 91764
US

Trademark Events

Event DateEvent Description
Tuesday, July 1, 2025NEW APPLICATION ENTERED
Tuesday, July 1, 2025APPLICATION FILING RECEIPT MAILED
Thursday, November 6, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, November 19, 2025ASSIGNED TO EXAMINER
Tuesday, November 25, 2025NON-FINAL ACTION WRITTEN
Tuesday, November 25, 2025NON-FINAL ACTION E-MAILED
Tuesday, November 25, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, December 3, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, December 3, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 3, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, December 3, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, December 3, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 3, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, January 9, 2026NON-FINAL ACTION WRITTEN
Friday, January 9, 2026NON-FINAL ACTION E-MAILED
Friday, January 9, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, January 11, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, January 11, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Sunday, January 11, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 10, 2026FINAL REFUSAL WRITTEN
Tuesday, February 10, 2026FINAL REFUSAL E-MAILED
Tuesday, February 10, 2026NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, February 11, 2026TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, February 11, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, February 11, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 6, 2026NON-FINAL ACTION WRITTEN
Friday, March 6, 2026NON-FINAL ACTION E-MAILED
Friday, March 6, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 11, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 11, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 11, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 6, 2026ACTION CONTINUING A FINAL - COMPLETED
Monday, April 6, 2026CONTINUATION OF FINAL REFUSAL E-MAILED
Monday, April 6, 2026NOTIFICATION OF SUBSEQUENT FINAL EMAILED

Related Keywords

drugreboot clinical trials information software scientific service failed trial features molecular